Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Chardan Capital restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock. ARWR has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an […]
More Stories
Rockhopper Exploration plc (OTCMKTS:RCKHF) Short Interest Update
Rockhopper Exploration plc (OTCMKTS:RCKHF – Get Free Report) was the recipient of a large increase in short interest in October....
Short Interest in MultiPlan Co. (NYSE:MPLN) Drops By 38.5%
MultiPlan Co. (NYSE:MPLN – Get Free Report) was the recipient of a large decline in short interest in the month...
AngioDynamics (NASDAQ:ANGO) versus NeuroOne Medical Technologies (NASDAQ:NMTC) Financial Analysis
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and AngioDynamics (NASDAQ:ANGO – Get Free Report) are both small-cap medical companies,...
Deutsche Wohnen SE (OTCMKTS:DWHHF) Short Interest Down 27.3% in October
Deutsche Wohnen SE (OTCMKTS:DWHHF – Get Free Report) was the target of a large decline in short interest in the...
Domino’s Pizza Group plc (OTCMKTS:DMPZF) Short Interest Update
Domino’s Pizza Group plc (OTCMKTS:DMPZF – Get Free Report) was the target of a large increase in short interest in...
Invesco AAA CLO Floating Rate Note ETF (BATS:ICLO) Declares Dividend of $0.13
Invesco AAA CLO Floating Rate Note ETF (BATS:ICLO – Get Free Report) declared a dividend on Friday, November 15th,NASDAQ Dividends...